J Am Coll Cardiol: 基因修饰干细胞促进衰老心肌再生

2012-08-07 范伟伟译 医学论坛网

  近期,美国心脏学会(AHA)心血管基础科学2012年科学会议的一篇报道指出,基因修饰的干细胞可促进衰老心脏细胞的活力,用于老年心力衰竭患者体内受损和衰老心肌组织的再生。这项研究有朝一日可能引领出新的心力衰竭治疗方法。该研究同时发表在2012年7月23日的《美国心脏病学会杂志》(J Am Coll Cardiol)。   主要研究者之一、美国圣迭戈州立大学心脏研究

  近期,美国心脏学会(AHA)心血管基础科学2012年科学会议的一篇报道指出,基因修饰的干细胞可促进衰老心脏细胞的活力,用于老年心力衰竭患者体内受损和衰老心肌组织的再生。这项研究有朝一日可能引领出新的心力衰竭治疗方法。该研究同时发表在2012年7月23日的《美国心脏病学会杂志》(J Am Coll Cardiol)。

  主要研究者之一、美国圣迭戈州立大学心脏研究所博士后研究学者萨迪亚·穆赫辛(Sadia Mohsin) 博士说,“由于心力衰竭患者通常都是老年人,他们的心脏干细胞多处在非健康状态。通过基因修饰方法,增加活体干细胞的端粒长度和活性,可以使这些细胞更加健康,再次恢复活力,这就好比是把钟表调慢;这种方法同时能够增加心脏干细胞增殖,这些都是抗心力衰竭的有效手段。”

  毋庸置疑,干细胞能够被用来对抗由端粒降解导致的心脏细胞衰老过程。端粒是位于染色体末端的“帽子”结构,可以促进细胞复制。当端粒破裂时,就会产生衰老和疾病。在实验室中,研究人员利用一种促进细胞存活和生长的蛋白PIM-1来修饰这些干细胞。经过修饰的人体干细胞,有助于恢复从老年人活组织中获取的心脏细胞的信号传导,并维持其正常结构。当修饰后的干细胞增强了端粒酶的活性时,端粒的长度便得以延长,心脏细胞即重获新生。尽管运用了人体干细胞,但是该研究目前仅局限于实验室。研究人员在小鼠和猪的体内测试这项技术,结果表明,在短短4周时间内,端粒的延​​长可导致新的心脏组织生长。

  穆赫辛说,“可以通过修饰老年患者的心脏细胞,增加细胞的再生能力,从而修复受损心肌;这种方法使干细胞工程成为心衰治疗的一种可行的选择。对于心力衰竭患者,这是一个令人特别振奋的发现。鉴于目前我们只能提供药物治疗、心脏移植或具有适度再生潜力的细胞治疗,PIM-1修饰的干细胞可能带来临床治疗的重大进步。

 

  



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781601, encodeId=d8b91e81601b0, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 19 00:15:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783280, encodeId=8a481e8328035, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Jan 17 22:15:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569251, encodeId=d44e15692517d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599927, encodeId=c946159992e6a, content=<a href='/topic/show?id=7a7d4168e3a' target=_blank style='color:#2F92EE;'>#基因修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41687, encryptionId=7a7d4168e3a, topicName=基因修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069c18767911, createdName=apoenzyme, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627019, encodeId=64f6162e01944, content=<a href='/topic/show?id=589051255a6' target=_blank style='color:#2F92EE;'>#心肌再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51255, encryptionId=589051255a6, topicName=心肌再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9eb21069251, createdName=俅侠, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781601, encodeId=d8b91e81601b0, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 19 00:15:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783280, encodeId=8a481e8328035, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Jan 17 22:15:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569251, encodeId=d44e15692517d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599927, encodeId=c946159992e6a, content=<a href='/topic/show?id=7a7d4168e3a' target=_blank style='color:#2F92EE;'>#基因修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41687, encryptionId=7a7d4168e3a, topicName=基因修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069c18767911, createdName=apoenzyme, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627019, encodeId=64f6162e01944, content=<a href='/topic/show?id=589051255a6' target=_blank style='color:#2F92EE;'>#心肌再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51255, encryptionId=589051255a6, topicName=心肌再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9eb21069251, createdName=俅侠, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=)]
    2013-01-17 waiwai3030
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781601, encodeId=d8b91e81601b0, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 19 00:15:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783280, encodeId=8a481e8328035, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Jan 17 22:15:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569251, encodeId=d44e15692517d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599927, encodeId=c946159992e6a, content=<a href='/topic/show?id=7a7d4168e3a' target=_blank style='color:#2F92EE;'>#基因修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41687, encryptionId=7a7d4168e3a, topicName=基因修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069c18767911, createdName=apoenzyme, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627019, encodeId=64f6162e01944, content=<a href='/topic/show?id=589051255a6' target=_blank style='color:#2F92EE;'>#心肌再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51255, encryptionId=589051255a6, topicName=心肌再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9eb21069251, createdName=俅侠, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=)]
    2012-08-09 zhangyxzsh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781601, encodeId=d8b91e81601b0, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 19 00:15:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783280, encodeId=8a481e8328035, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Jan 17 22:15:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569251, encodeId=d44e15692517d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599927, encodeId=c946159992e6a, content=<a href='/topic/show?id=7a7d4168e3a' target=_blank style='color:#2F92EE;'>#基因修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41687, encryptionId=7a7d4168e3a, topicName=基因修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069c18767911, createdName=apoenzyme, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627019, encodeId=64f6162e01944, content=<a href='/topic/show?id=589051255a6' target=_blank style='color:#2F92EE;'>#心肌再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51255, encryptionId=589051255a6, topicName=心肌再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9eb21069251, createdName=俅侠, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1781601, encodeId=d8b91e81601b0, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 19 00:15:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783280, encodeId=8a481e8328035, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Jan 17 22:15:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569251, encodeId=d44e15692517d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599927, encodeId=c946159992e6a, content=<a href='/topic/show?id=7a7d4168e3a' target=_blank style='color:#2F92EE;'>#基因修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41687, encryptionId=7a7d4168e3a, topicName=基因修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069c18767911, createdName=apoenzyme, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627019, encodeId=64f6162e01944, content=<a href='/topic/show?id=589051255a6' target=_blank style='color:#2F92EE;'>#心肌再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51255, encryptionId=589051255a6, topicName=心肌再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9eb21069251, createdName=俅侠, createdTime=Thu Aug 09 05:15:00 CST 2012, time=2012-08-09, status=1, ipAttribution=)]

相关资讯

Neuron:胚胎干细胞用于治疗神经性疼痛

近日,加州大学旧金山分校的科学家们发现使用胚胎干细胞能用来治疗神经性疼痛。 加州大学旧金山分校的科学家完成的一项新研究证实:细胞疗法可能有一天被用来治疗一些常见类型的疼痛症状。 研究人员在小鼠身上开展的研究,关注于治疗神经损伤引起的慢性疼痛即所谓的神经性疼痛。 相关研究论文发表在Neuron杂志上,在他们的研究中,科学家们在老鼠大脑中移植不成熟的胚胎神经细胞,在大脑中神经细胞被用来更新特定的

Stem Cell :抗体捕获癌干细胞或成为癌症治疗新手段

近日,一个国际研究小组通过研究揭示了一种新的标记物,这种新的标记物对于我们理解癌症在肝脏、胰脏以及食道中的发展至关重要。相关研究成果刊登在了近日的国际杂志Stem Cell 上。我们熟知的干细胞一般“居住”于器官中,一般情况下,使干细胞分离非常困难。研究者的这项研究揭示了一种抗体可以用于捕获干细胞。 研究者Pera教授表示,这种抗体可以检测疾病状态下的器官祖细胞,比如肝硬化或者胰腺癌等癌症。通过

陈东风:肝脏再生过程中干细胞分化调控机制的研究进展

作者 重庆第三军医大学大坪医院 陈东风        【前言】以下内容来源于第五届全国肝病免疫与生物治疗研讨会上,陈东风教授的发言综述了肝脏肝细胞在肝损伤中的作用及其机制,敬请阅读~ &nbs

Cell:干细胞发育触发记忆形成

大脑细胞如何能既记住新记忆同时又不忘记旧记忆?科学家已找到了这方面的答案。他们发现,大脑齿状回区域中的特异神经元在记忆形成中起了明显作用,取决于产生神经元的神经干细胞是年纪大还是年轻。 这项研究将在三月三十日的Cell上,它将记忆形成分子基础与新神经元产生联系起来,这项发现将揭示治疗记忆疾病的新一类药物靶标。 这项发现也表明,大脑中年轻神经元与年长神经元间的不平衡可能瓦解创伤后精神紧张性(精神

PNAS:干细胞在幼年个体而非成年个体中分化为心脏细胞

近日,来自康奈尔大学和伯恩大学的研究者研究指出,在人们早年时心脏病发作后,干细胞实际上可以取代坏死的心脏组织,但是这些干细胞在人成年后会丧失再生的能力。这项研究中,研究者使用小鼠作为研究模型发现未分化的前体细胞在两天大的小鼠体内可以分化为心脏细胞,但是在成体小鼠中却不行。 目前在成年个体中是否存在未分化的前体干细胞仍存在争议,如果在成年个体中确实存在有能力的干细胞,为何在个体梗塞之后没有新的心脏

日用iPS细胞培育出癌症干细胞

诱导多功能干细胞(iPS细胞)能发育成各种组织和脏器,但医学家担心它们发生癌变。日本研究人员13日报告说,他们用小鼠iPS细胞培育出了癌症干细胞,并确认其发展成癌细胞的过程,这将有助于提高iPS细胞的安全性。   日本冈山大学教授妹尾昌治领导的研究小组13日在美国在线科学刊物《PLoS综合》上报告说,他们首先用小鼠细胞培育出iPS细胞,然后向培养液中添加曾培育过肺癌、皮肤